Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours
- 19 May 2004
- journal article
- review article
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 31 (7), 1038-1046
- https://doi.org/10.1007/s00259-004-1571-4
Abstract
Somatostatin receptors are over-expressed in many tumours, mainly of neuroendocrine origin, thus enabling treatment with somatostatin analogues. Almost a decade of clinical experience of receptor radionuclide therapy with the analogue 90Y-[DOTA]0-Tyr3-octreotide [90Y-DOTATOC] has now been obtained at a few centres of excellence. This review reports on the present state of the art of receptor radionuclide therapy and discusses new perspectives.Keywords
This publication has 38 references indexed in Scilit:
- Radiolabelled peptides for tumour therapy: current status and future directionsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.2002
- New advances in peptide receptor radionuclide therapy.2002
- Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findingsSeminars in Nuclear Medicine, 2002
- Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.2001
- End-stage renal disease after treatment with 90 Y-DOTATOCEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancerBritish Journal of Cancer, 1999
- Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-upBritish Journal of Cancer, 1998
- Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: A study by the Italian Trials in Medical Oncology groupCancer, 1996
- Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993